Long-Term Use of Short-Acting β2-Agonists in Patients With Adult-Onset Asthma

    Research output: Contribution to journalArticleScientificpeer-review

    3 Downloads (Pure)


    Background: Short-term studies have associated high use of short-acting β2-agonists (SABA) with increased risk of exacerbations, emergency visits, and asthma-related costs. However, no studies exist on long-term SABA use, and previous studies on the topic have not included information about adherence to inhaled corticosteroids (ICS) nor disease control, both affecting the need of SABA. Objective: To evaluate the clinical characteristics of SABA and ICS usage in newly diagnosed adult-onset asthma patients during a 12-year follow-up period. Methods: In the Seinäjoki Adult Asthma Study, 203 patients with adult-onset asthma were followed for 12 years. Information on dispensed SABA and ICS during the follow-up was obtained from the Finnish Social Insurance Institution. High SABA use was defined as ≥36 canisters in 12 years, corresponding to an average of ≥3 dispensed canisters/y. Results: Patients were dispensed median 6 (interquartile range: 3-16) SABA canisters and 48 (18-67) ICS canisters over 12 years, corresponding to 2 (1-4) and 11 (5-16) puffs/week, respectively. Only 10% of the patients were classified as high SABA users during this period. Obesity (body mass index ≥30) and high Airways Questionnaire 20 symptom scores at baseline predicted high long-term SABA use (incidence rate ratio: 1.53 [1.01-2.30] and 1.04 [1.00-1.08], respectively). High SABA users had higher ICS adherence, higher blood neutrophil counts, more comorbidities, and used more oral corticosteroid and antibiotic courses versus low SABA users. Conclusion: High SABA use was infrequent in patients with confirmed adult-onset asthma. However, as high SABA use is associated with more severe asthma, these patients should be recognized in clinical practice.

    Original languageEnglish
    Pages (from-to)2074-2083.e7
    JournalJournal of Allergy and Clinical Immunology: In Practice
    Issue number8
    Publication statusPublished - Apr 2022
    Publication typeA1 Journal article-refereed


    • Adult-onset
    • Asthma
    • Asthma control
    • Asthma treatment
    • Follow-up
    • Long-term
    • Obesity
    • Prognosis
    • Reliever therapy
    • Short-acting β-agonists

    Publication forum classification

    • Publication forum level 1

    ASJC Scopus subject areas

    • Immunology and Allergy


    Dive into the research topics of 'Long-Term Use of Short-Acting β2-Agonists in Patients With Adult-Onset Asthma'. Together they form a unique fingerprint.

    Cite this